FDA grants orphan drug designation to oral OCT-980 for RHO-adRP, now in phase 1b/2 testing at US sites.
News|Articles|January 15, 2026
Optometry pipeline watch: Key trial results and PDUFA dates for Q1 2026
Author(s)Lynda Charters
Fact checked by: Kelly King
Key clinical trial data and PDUFA dates in early 2026 focus on treatments for dry eye, age-related macular degeneration, and rare eye diseases.
Advertisement
Advertisement
Editor's Note: This content was generated with the assistance of AI.
Related to this article
Interim 48-month data show 86% of patients with glaucoma or ocular hypertension remain off topical drops after a single cataract procedure, although the drop-free rate has eased from earlier timepoints.
CLARITY program data show significantly longer time to treatment failure and higher rates of steroid-free quiescence vs placebo.
Duravyu gained 2.5 letters vs 6.1 with aflibercept at week 52/56, missing noninferiority in a second phase 3 wet AMD trial.
Enspryng is the first subcutaneous, at-home treatment option for TED and the first IL-6 receptor inhibitor approved for this indication.
Three researchers share the prize for discovering channelrhodopsin, a light-sensitive protein now being tested to restore vision in retinal disease.
FDA advisers review SYD-101, low-dose atropine 0.01% for pediatric myopia, on Oct 30 after a 2025 complete response letter.
Lloyd Williams, MD, PhD, discusses rising cataract blindness and low-cost surgery in conflict zones for World Sight Day.
Advertisement
Advertisement